TORNALATE
LOE ApproachingNDAINHALATIONSOLUTION
Approved
Feb 1992
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TORNALATE is an inhaled small-molecule bronchodilator approved in 1992 for respiratory indications. The specific mechanism of action and clinical indications are not publicly detailed in available data. This is a legacy product in the mature phase of its commercial lifecycle.
LOE Approaching
As LOE approaches, the brand team is likely contracting; career growth is limited unless assigned to cost-management or transition roles.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on TORNALATE offers limited career advancement due to zero linked job openings and LOE-approaching lifecycle status. Professionals assigned to this product should expect team right-sizing and prioritize transition planning to higher-growth brands within Sanofi's portfolio.
Brand Manager (legacy)Commercial Operations
Worked on TORNALATE at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.